Page 1130 - Clinical Immunology_ Principles and Practice ( PDFDrive )

ChaPter 80 Monoclonal Gammopathies 1093.e1

MUL ti PL e -C h O i C e QU e S ti ONS

1. Which of the following is a “myeloma defining event“ according 3. Which one of these differentiates Waldenström macroglobu-
to the 2014 International Myeloma Working Group (IMWG) linemia (WM) from IgM MGUS?
guidelines? A. IgM M-protein ≥1 g/dL
A. One focal 4-mm lesion on magnetic resonance imaging B. ≥10% plasma cells in bone marrow
B. M-protein >0.5 g/dL C. Renal damage
C. Back pain D. Patient age <50
D. Clonal bone marrow plasma cells ≥60%
2. Which one of these is a risk factor for progression from
monoclonal gammopathy of undetermined significance
(MGUS) to multiple myeloma or a related malignancy?
A. Immunoglobulin G (IgG) MGUS
B. Abnormal serum free light chain ratio
C. M-protein ≥0.3 g/dL
D. Patient age >50